Literature DB >> 28839978

Target blood pressure and cardiovascular risk.

Céline Dreyfuss-Tubiana1, Philippe Sosner1, Jacques Blacher1.   

Abstract

Year:  2017        PMID： 28839978      PMCID： PMC5543006          DOI： 10.21037/jtd.2017.06.125

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

1.  Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study.

Authors:  Jacques Blacher; Alun Evans; Dominique Arveiler; Philippe Amouyel; Jean Ferrières; Annie Bingham; John Yarnell; Bernadette Haas; Michèle Montaye; Jean-Bernard Ruidavets; Pierre Ducimetière
Journal:  J Hypertens       Date:  2004-02       Impact factor: 4.844

2.  Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited.

Authors:  Johannes A N Dorresteijn; Yolanda van der Graaf; Wilko Spiering; Diederick E Grobbee; Michiel L Bots; Frank L J Visseren
Journal:  Hypertension       Date:  2011-11-07       Impact factor: 10.190

3.  Low diastolic blood pressure was one of the independent predictors of ischemia-like findings of electrocardiogram in patients who underwent coronary angiography.

Authors:  Shinichiro Fujishima; Noboru Murakami; Yoshie Haga; Eiji Nyuta; Yuuki Nakate; Shiro Ishihara; Shigeru Kaseda; Tokushi Koga; Takao Ishitsuka
Journal:  J Cardiol       Date:  2013-06-24       Impact factor: 3.159

4.  Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate.

Authors:  G Mancia; G Bertinieri; G Grassi; G Parati; G Pomidossi; A Ferrari; L Gregorini; A Zanchetti
Journal:  Lancet       Date:  1983-09-24       Impact factor: 79.321

Review 5.  Studies on arterial stiffness and wave reflections in hypertension.

Authors:  Michel E Safar; Bernard I Levy
Journal:  Am J Hypertens       Date:  2014-09-02       Impact factor: 2.689

6.  Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).

Authors:  Krishna K Patel; Suzanne V Arnold; Paul S Chan; Yuanyuan Tang; Yashashwi Pokharel; Philip G Jones; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-04

7.  Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.

Authors:  Michael Böhm; Helmut Schumacher; Koon K Teo; Eva M Lonn; Felix Mahfoud; Johannes F E Mann; Giuseppe Mancia; Josep Redon; Roland E Schmieder; Karen Sliwa; Michael A Weber; Bryan Williams; Salim Yusuf
Journal:  Lancet       Date:  2017-04-05       Impact factor: 79.321

8.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

9.  Relative Contributions of Arterial Stiffness and Hypertension to Cardiovascular Disease: The Framingham Heart Study.

Authors:  Teemu J Niiranen; Bindu Kalesan; Naomi M Hamburg; Emelia J Benjamin; Gary F Mitchell; Ramachandran S Vasan
Journal:  J Am Heart Assoc       Date:  2016-10-26       Impact factor: 5.501

Review 10.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

Authors:  Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers
Journal:  Lancet       Date:  2015-11-07       Impact factor: 79.321
View more
  1 in total

1.  Target blood pressure in high risk cardiovascular patients.

Authors:  Dominic Millenaar; Sebastian Ewen; Felix Mahfoud; Michael Böhm
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.